Panel: Designing CGTs in the age of agentic AI: How to accelerate discovery and development without losing regulatory control

From optional to inevitable: Where agentic and analytical AI are already changing discovery and early CGT development and what must be true for AI to become a trusted, default tool rather than a pilot experiment.

Beyond prediction to intervention: How next-generation AI is moving past predictive modelling into active roles in target identification, vector and capsid design, and optimisation of early development decisions, shortening timelines without eroding scientific judgement.

Data foundations determine outcomes: What clinical and preclinical data strategies, governance models and hygiene standards must be in place to unlock advanced AI capabilities—while staying inspection-ready as the EU AI Act comes into force.

Regulation without paralysis: What the EU AI Act actually means for CGT developers: where the real risks sit, where flexibility exists, and how teams can avoid over-engineering compliance or freezing innovation through misinterpretation.

Building AI-ready CGT organisations: Who the right collaboration partners are, what internal structures need to change, and which skills and talent profiles are now essential to embed agentic and analytical AI into product design, not bolt it on.